Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cholesterol induced regulator of metabolism RNA (CHROMR, also known as CHROME or PRKRA-AS1) is a primate-specific long non-coding RNA located on human chromosome 2q31.2. CHROMR is upregulated in plasma and arterial plaques of patients with cardiovascular disease, and its expression is regulated by sterol-activated LXR transcription factors. Functionally, CHROMR promotes cholesterol efflux and HDL synthesis by inhibiting the activity of specific microRNAs (miR-27b, miR-33a/b, miR-128) that otherwise suppress ABCA1, an essential gene for HDL formation. Knockdown of CHROMR reduces cholesterol efflux and impairs nascent HDL biogenesis. CHROMR is being explored as a biomarker and experimental regulator for cholesterol-related diseases but is not a direct drug target, nor is it a receptor, enzyme, or transporter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cholesterol induced regulator of metabolism RNA (CHROMR).